Accelerant Q3 10-Q: $9.2M Net Loss, Loss Ratio Jumps to 56.8%, $8.6M Out-of-Period Charge
ARX has more than doubled off its 52-week low of $9.18 on light trading volume (0.3× avg).
Summary
Accelerant's Q3 10-Q shows a $9.2M net loss and a gross loss ratio of 56.8%, up from 50.1%, plus an $8.6M out-of-period ceding commission charge — detail beyond the same-day earnings release, against the backdrop of the pending $20.25/share Thoma Bravo buyout.
Key Events · Earnings and Guidance · ARX
-
Q3 Swing to Net Loss
Total revenues were $278.6M but net loss was $9.2M, or $0.06 per diluted share, versus nine-month net income of $66.7M.
-
Loss Ratio Deteriorates
Gross loss ratio rose to 56.8% in Q3 2026 from 50.1% a year earlier; the net loss ratio held at 61.9%.
-
$8.6M Out-of-Period Charge
An out-of-period ceding commission adjustment increased loss before income taxes by $8.6M, including $5.1M related to 2025 and prior; management deemed it immaterial to prior statements.
-
Sliding Scale Commissions Cut
Unfavorable loss experience reduced ceding commission income by $10.6M in Q3 and $17.7M for the nine months.
Analysis · ARX · Finance
The headline premium growth is already public, but the full 10-Q reveals a weaker quarter underneath: a $9.2M net loss, a gross loss ratio up to 56.8% from 50.1%, and an $8.6M out-of-period ceding commission charge (including $5.1M tied to 2025 and prior). Sliding scale commissions cut ceding commission income by $10.6M in the quarter and $17.7M year-to-date as loss experience turned unfavorable. With the $20.25-per-share Thoma Bravo deal pending and expected to close in the first half of 2027, the operating numbers matter less for the share price than for deal risk — a sustained loss-ratio deterioration is the kind of thing that could feed a material-adverse-effect argument, though nothing in the filing suggests that. The company also disclosed it expects to sell or transfer its Canadian insurance subsidiary to Altamont Capital Partners ahead of closing, and A.M. Best has put its A- carrier ratings under review with developing implications.
How filings like this one have moved
In the 30 days to Nov 11, 2026, 36.6% of the 3434 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ARX was trading at $19.87 on NYSE in the Finance sector, with a market capitalization of approximately $4.3B. The 52-week trading range was $9.18 to $19.91. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.